Arjuna Capital Invests $1.38 Million in Cencora, Inc. (NYSE:COR)

Arjuna Capital acquired a new position in Cencora, Inc. (NYSE:COR - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 4,978 shares of the company's stock, valued at approximately $1,384,000.

Several other institutional investors have also recently made changes to their positions in the company. Proficio Capital Partners LLC bought a new position in shares of Cencora in the 4th quarter worth $31,936,000. Independent Advisor Alliance boosted its stake in shares of Cencora by 64.7% during the fourth quarter. Independent Advisor Alliance now owns 1,659 shares of the company's stock worth $373,000 after buying an additional 652 shares during the period. Moors & Cabot Inc. increased its stake in shares of Cencora by 3.4% during the 4th quarter. Moors & Cabot Inc. now owns 1,991 shares of the company's stock worth $447,000 after purchasing an additional 66 shares in the last quarter. HighTower Advisors LLC grew its stake in shares of Cencora by 0.5% during the 4th quarter. HighTower Advisors LLC now owns 129,794 shares of the company's stock valued at $29,162,000 after buying an additional 704 shares during the period. Finally, Sequoia Financial Advisors LLC increased its holdings in shares of Cencora by 8.2% in the 4th quarter. Sequoia Financial Advisors LLC now owns 7,174 shares of the company's stock valued at $1,612,000 after acquiring an additional 544 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Insider Buying and Selling at Cencora

In other Cencora news, Chairman Steven H. Collis sold 14,579 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total value of $4,266,106.98. Following the completion of the sale, the chairman owned 311,913 shares in the company, valued at approximately $91,271,982.06. This trade represents a 4.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of the business's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer owned 47,582 shares in the company, valued at $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 34,127 shares of company stock valued at $9,812,296. 10.80% of the stock is owned by company insiders.

Cencora Price Performance

Shares of COR traded down $2.60 during trading hours on Tuesday, reaching $294.46. 367,929 shares of the company traded hands, compared to its average volume of 1,506,083. The stock has a market capitalization of $57.07 billion, a PE ratio of 34.16, a price-to-earnings-growth ratio of 1.46 and a beta of 0.57. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35. The stock has a fifty day simple moving average of $291.91 and a 200 day simple moving average of $270.29.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same quarter in the prior year, the company earned $3.80 EPS. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date was Friday, May 16th. Cencora's payout ratio is 25.52%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on COR. Jefferies Financial Group increased their price target on shares of Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a research note on Monday, June 30th. Citigroup raised their price target on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Bank of America raised their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. UBS Group increased their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Finally, Wells Fargo & Company raised Cencora from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $274.00 to $337.00 in a research report on Tuesday, June 3rd. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $306.33.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.